MCS 2
Alternative Names: Bo Yongso; Botreso; MCS-2; Multi-carotenoids; MUSLatest Information Update: 09 Dec 2025
At a glance
- Originator Health Ever Bio-Tech
- Class Carotenoids; Plant proteins; Urologics
- Mechanism of Action Antioxidants; Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Benign prostatic hyperplasia
Most Recent Events
- 04 Dec 2025 Jyong Biotech signs non-binding memorandum of Understanding (MOU) with Vietnam-based pharmaceutical distribution company to evaluate the development and commercialization of MCS 2
- 02 Dec 2025 MCS 2 is available for licensing as of 02 Dec 2025. https://jyongbio.com/research-and-development (Jyong Biotech pipeline, December 2025)
- 24 Nov 2025 Jyong Biotech signs non-binding letter of intent (LOI) with South Korean Pharmaceutical Company to evaluate in-licensing of MCS 2